AVBP vs RCUS vs TPVG vs HALO vs KYMR

For growth investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger pick with 37. 6% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). TriplePoint Venture Growth BDC Corp. (TPVG) offers the better valuation at 4. 9x trailing P/E (6. 5x forward), making it the more compelling value choice. Analysts rate ArriVent BioPharma, Inc. Common Stock (AVBP) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, TriplePoint Venture Growth BDC Corp.

(TPVG) is the cheapest at 4. 9x versus Halozyme Therapeutics, Inc. at 25. 5x. On forward P/E, TriplePoint Venture Growth BDC Corp. is actually cheaper at 6. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Halozyme Therapeutics, Inc. wins at 0. 35x versus TriplePoint Venture Growth BDC Corp. 's 6. 41x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Kymera Therapeutics, Inc.

(KYMR) delivered a total return of +92. 1%, compared to -18. 6% for Arcus Biosciences, Inc. (RCUS). Over 10 years, the gap is even starker: HALO returned +570. 7% versus AVBP's +44. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 56β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 250% more volatile than HALO relative to the S&P 500. On balance sheet safety, ArriVent BioPharma, Inc. Common Stock (AVBP) carries a lower debt/equity ratio of 0% versus 133% for TriplePoint Venture Growth BDC Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Halozyme Therapeutics, Inc.

(HALO) is pulling ahead at 37. 6% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: TriplePoint Venture Growth BDC Corp. grew EPS 48. 8% year-over-year, compared to -68. 8% for ArriVent BioPharma, Inc. Common Stock. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TriplePoint Venture Growth BDC Corp.

(TPVG) is the more profitable company, earning 50. 6% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Halozyme Therapeutics, Inc. (HALO) is the more undervalued stock at a PEG of 0. 35x versus TriplePoint Venture Growth BDC Corp. 's 6. 41x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, TriplePoint Venture Growth BDC Corp. (TPVG) trades at 6. 5x forward P/E versus 8. 1x for Halozyme Therapeutics, Inc. — 1. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AVBP: 52. 5% to $44. 00.

In this comparison, TPVG (17.

1% yield) pays a dividend. AVBP, RCUS, HALO, KYMR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +570. 7%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AVBP (Healthcare) and RCUS (Healthcare) and TPVG (Financial Services) and HALO (Healthcare) and KYMR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AVBP is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; TPVG is a small-cap high-growth stock; HALO is a small-cap high-growth stock; KYMR is a small-cap quality compounder stock. TPVG pays a dividend while AVBP, RCUS, HALO, KYMR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.